Trials / Completed
CompletedNCT06727396
A Study to Investigate the Safety, Tolerability, PK, and PD of CKD-508 in Healthy Participants
A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, Single Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CKD-508 in Healthy Participants.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Chong Kun Dang Pharmaceutical · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This Phase 1, randomized, parallel-group, placebo-controlled, double-blinded study aims to evaluate the safety, PK, and PD of CKD-508 when administered multiple times once daily to healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CKD-508 Tablet | Investigational drug |
| DRUG | Placebo Tablet | Placebo |
Timeline
- Start date
- 2024-11-14
- Primary completion
- 2025-06-05
- Completion
- 2025-06-05
- First posted
- 2024-12-10
- Last updated
- 2026-02-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06727396. Inclusion in this directory is not an endorsement.